X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (68) 68
index medicus (67) 67
humans (60) 60
female (41) 41
cancer (32) 32
tumors (23) 23
animals (20) 20
middle aged (20) 20
aged (17) 17
adult (16) 16
breast cancer (16) 16
mice (16) 16
breast neoplasms - pathology (15) 15
immunohistochemistry (15) 15
metastasis (15) 15
breast neoplasms - drug therapy (14) 14
male (14) 14
pathology (14) 14
gene expression (13) 13
biomarkers (12) 12
breast neoplasms - genetics (12) 12
breast-cancer (12) 12
gene expression regulation, neoplastic (12) 12
mutation (11) 11
receptor, erbb-2 - metabolism (11) 11
breast neoplasms - metabolism (10) 10
cell line, tumor (10) 10
expression (10) 10
prognosis (10) 10
research (10) 10
aged, 80 and over (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
cell biology (9) 9
cell proliferation (9) 9
genetic aspects (9) 9
medicine, research & experimental (9) 9
neoplasms (9) 9
trastuzumab (9) 9
article (8) 8
cells (8) 8
chemotherapy (8) 8
melanoma (8) 8
multidisciplinary sciences (8) 8
neoadjuvant therapy (8) 8
neoplasm staging (8) 8
receptor, erbb-2 - antagonists & inhibitors (8) 8
survival (8) 8
activation (7) 7
analysis (7) 7
biomarkers, tumor - genetics (7) 7
breast neoplasms - mortality (7) 7
dna damage (7) 7
gene expression profiling (7) 7
melanoma - pathology (7) 7
skin and connective tissue diseases (7) 7
treatment outcome (7) 7
tumorigenesis (7) 7
xenograft model antitumor assays (7) 7
adjuvant chemotherapy (6) 6
biomarkers, tumor - metabolism (6) 6
genes (6) 6
genomics (6) 6
growth (6) 6
immunotherapy (6) 6
lymphocytes (6) 6
metastases (6) 6
mutations (6) 6
patients (6) 6
protein binding (6) 6
proteins (6) 6
quinazolines - administration & dosage (6) 6
receptor, erbb-2 - genetics (6) 6
trastuzumab - therapeutic use (6) 6
abridged index medicus (5) 5
biopsy (5) 5
cancer therapies (5) 5
carcinogenesis (5) 5
care and treatment (5) 5
chemotherapy, adjuvant (5) 5
drug resistance, neoplasm (5) 5
gene (5) 5
her2 (5) 5
inhibitors (5) 5
kinases (5) 5
lung neoplasms - pathology (5) 5
melanoma - genetics (5) 5
mice, nude (5) 5
multicenter (5) 5
neoplasm invasiveness (5) 5
oligonucleotide array sequence analysis (5) 5
open-label (5) 5
pathway (5) 5
proportional hazards models (5) 5
signal transduction (5) 5
signal transduction - drug effects (5) 5
surgery (5) 5
antineoplastic agents - therapeutic use (4) 4
beta-catenin (4) 4
biomarkers, tumor - analysis (4) 4
clinical trials (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 545 - 554
Journal Article
Science, ISSN 0036-8075, 12/2017, Volume 358, Issue 6369, pp. 1443 - 1448
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 9, pp. 2213 - 2221
Journal Article
Translational Cancer Research, ISSN 2218-676X, 2016, Volume 5, Issue S3, pp. S569 - S571
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 07/2017, Volume 77, Issue 13, pp. 3540 - 3550
Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety of solid tumors, but most patients exhibit partial or... 
BREAST-CANCER | BIOMARKERS | ANTI-PD-1 THERAPY | PEMBROLIZUMAB | ONCOLOGY | CLINICAL ONCOLOGY/COLLEGE | RECOMMENDATIONS | SENSITIVITY | MECHANISMS | TUMORS | AMERICAN SOCIETY | Gene Expression - drug effects | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Squamous Cell Carcinoma of Head and Neck | Melanoma - genetics | Gene Expression - immunology | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Head and Neck Neoplasms - drug therapy | Gene Expression Profiling - methods | Melanoma - pathology | Head and Neck Neoplasms - pathology | Carcinoma, Non-Small-Cell Lung - immunology | Lung Neoplasms - immunology | Carcinoma, Squamous Cell - drug therapy | Melanoma - immunology | Melanoma - drug therapy | Nivolumab | Head and Neck Neoplasms - genetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | PD-1 protein | CD8 antigen | Lung | Antibodies | Activation | Lymphocytes T | Killer cells | Cell activation | Lymphocytes | Bioindicators | Neck | Natural killer cells | Signatures | Squamous cell carcinoma | Head | Immune response | Small cell lung carcinoma | Tumor-infiltrating lymphocytes | Melanoma | Lung carcinoma | Gene expression | Ribonucleic acid--RNA | Patients | CD4 antigen | Immune systems | Immune checkpoint | Reproducibility | PD-L1 protein | Biomarkers | Head and neck cancer | Interferon | Solid tumors | Cancer | Tumors | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 81, pp. 142 - 150
Abstract Background and objectives S49076 is a novel ATP-competitive tyrosine kinase inhibitor of MET, AXL and FGFR with a unique selectivity profile. A phase... 
Hematology, Oncology and Palliative Medicine | Tyrosine kinase inhibitor | Phase I clinical trial | MET inhibitor | AXL inhibitor | FGFR inhibitor | Metastasis | S49076 | Primary cancer | BEVACIZUMAB | MESENCHYMAL TRANSITION | CANCER | EGFR | ONCOGENE | ONCOLOGY | AXL | RESISTANCE | RECEPTORS | MET | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Thiazolidinediones - adverse effects | Thiazolidinediones - pharmacokinetics | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Thiazolidinediones - therapeutic use | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Adult | Female | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Tumors | Clinical trials | Fibroblast growth factors | Protein kinases | Analysis | Slopes | Toxicity | Pharmacology | Criteria | Kinases | Patients | Anticancer properties | Axl protein | Studies | c-Met protein | Inhibitors | Safety engineering | Solid tumors | Protein-tyrosine kinase | Cancer | Fibroblast growth factor receptors | Index Medicus
Journal Article